Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 9:36 PM
Ignite Modification Date:
2025-12-25 @ 7:19 PM
NCT ID:
NCT04604132
Recruitment Details:
From 6 Oct. 2020 to 10 Jun. 2022, 919 patients (pt.) had molecular pre-screening. 66 had clinical screening, and 47 were treated.
In Substudy 2, pt. were allocated to 1 of 3 dose levels using a dose escalation scheme: Derazantinib at a dose of 200 mg once daily, 300 mg once daily, or 200 mg twice daily, all in combination with paclitaxel and ramucirumab. However, no pt. received the highest dose, therefore only the 200 and 300 mg once daily dose levels are presented in the results section.
Study:
NCT04604132
Study Brief:
Results Section:
NCT04604132